Share
Dr. William G. Kaelin Jr.
IQVIA, a leading global provider of clinical research services, commercial insights, and healthcare intelligence, has appointed Dr. William G. Kaelin Jr. to its Board of Directors.
The appointment adds world-class scientific and clinical expertise to IQVIA’s board as the company continues to support innovation across the life sciences ecosystem.
Dr. Kaelin is a renowned physician-scientist and a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston. He also serves as the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School and is an Investigator at the Howard Hughes Medical Institute. Widely recognized for his contributions to cancer biology, Dr. Kaelin was awarded the 2019 Nobel Prize in Physiology or Medicine for his groundbreaking discoveries on cellular oxygen sensing and the role of the von Hippel-Lindau (VHL) tumor suppressor protein.
In addition to his academic and clinical roles, Dr. Kaelin brings valuable industry and governance experience. He currently serves on the Board of Directors of Eli Lilly and Company, where he also chairs the Science and Technology Committee, contributing to strategic oversight of research and innovation initiatives.
Dr. Kaelin has received numerous prestigious honors beyond the Nobel Prize, including the Albert Lasker Basic Medical Research Award, the Wiley Prize in Biomedical Sciences, the Paul Marks Prize for Cancer Research, and the Canada Gairdner International Award. He has authored hundreds of peer-reviewed scientific publications and holds multiple patents related to cancer biology and hypoxia signaling.
Dr. Kaelin earned his Doctor of Medicine degree from Duke University School of Medicine and holds a Bachelor of Arts in Mathematics and an Associate Bachelor’s degree in Chemistry from Duke University. His appointment strengthens IQVIA’s scientific leadership and commitment to advancing data-driven healthcare innovation.
Related posts
